Adagio Medical Presents Ultralow Temperature Ablation Study Results

Got story updates? Submit your updates here. ›

Adagio Medical Holdings, Inc., a leading innovator in catheter ablation technologies, announced that results from its U.S. pivotal study on its ultralow temperature ablation system will be presented in a late-breaking session at an upcoming major medical conference. The company's innovative approach aims to improve patient outcomes in cardiac ablation procedures.

Why it matters

Adagio's ultralow temperature ablation system represents a potential advancement in cardiac ablation technology, which is a common procedure used to treat heart rhythm disorders. Improved ablation techniques can lead to better patient safety and long-term outcomes, making this an important development in the field of cardiac electrophysiology.

The details

Adagio's U.S. pivotal study evaluated the safety and efficacy of its ultralow temperature ablation system, which uses extremely cold temperatures to destroy targeted heart tissue and restore normal heart rhythm. The late-breaking presentation at the upcoming medical conference will provide detailed results from this pivotal clinical trial.

• Adagio Medical announced the upcoming late-breaking presentation on April 1, 2026.

What’s next

The late-breaking presentation of Adagio's pivotal study results will provide important clinical data that could support regulatory approval and adoption of the company's ultralow temperature ablation system.